Nanosys, Harvard License Biosensor Patents to Vista Therapeutics | GenomeWeb

NEW YORK (GenomeWeb News) – Nanosys and Harvard University have licensed certain patents and patent applications to Vista Therapeutics covering the use of nanowires for biosensors.

Under terms of the license, Louisville, Ky.-based Vista has received exclusive, worldwide rights to use nanowires for detection of biomarkers associated with organ or tissue damage, as well as any form of treatment-associated adverse response. In return, Harvard and Nanosys have received an undisclosed equity stake in Vista, upfront license fees, and will receive downstream royalty payments.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.